Suspected Interference in E-Cigarette Regulation by Special Interest Groups

Sep.20.2024
Suspected Interference in E-Cigarette Regulation by Special Interest Groups
Indonesian MP Mukhamad Misbakhun suspects certain interest groups influencing e-cigarette regulations for potential company benefits.

According to the Indonesian media Liputan6 on September 19, 2024, Mukhamad Misbakhun, a member of the eleventh committee of the House of Representatives of the Republic of Indonesia, suspects that certain interest groups are interfering with the regulations in the draft Ministerial Regulation on the Safety of Tobacco and E-cigarette Products (RPMK), which could benefit certain e-cigarette companies.


Mr. Misbah pointed out that there is inconsistency between Article 3 and Article 7 of the draft. Article 3, paragraph 1 of the Tobacco Control Regulations stipulates that the scope of application of the Minister of Health's regulations includes standardizing the packaging of tobacco products and e-cigarette products. Paragraph 3 of Article 3 further specifies that e-cigarette products include the following: open or refillable nicotine e-liquid systems; closed or disposable pod systems; and solid forms.


However, the first provision of Article 7 regarding standardized packaging only covers open system or refillable e-cigarette products. The second provision of Article 7 regulates the packaging of closed systems (i.e. pods). Misbah emphasized that solid e-cigarettes have not been further regulated, and he suspects that there may be influence from global tobacco companies requesting the Ministry of Health not to regulate and control solid e-cigarettes, as these products are mainly imported solid products.


Previously, the government regulation issued by the Ministry of Health on 28/2024 had sparked opposition from various parties, including stakeholders in the tobacco industry. Currently, the Ministry of Health is finalizing the RPMK draft, however, this draft is also facing criticism and opposition from various sides.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.
Oct.27 by 2FIRSTS.ai
KT&G Q3 Net Profit Up 73%; Overseas NGP Revenue Nearly Doubles, Nicotine Pouch Expansion Set to Launch Globally
KT&G Q3 Net Profit Up 73%; Overseas NGP Revenue Nearly Doubles, Nicotine Pouch Expansion Set to Launch Globally
KT&G reported its Q3 2025 financial results, posting revenue of KRW 1.83 trillion (≈USD 1.31 billion) and a 73.4% year-over-year surge in net profit—marking the company’s highest operating profit in five years. The Next Generation Product (NGP) segment performed strongly, generating KRW 279.1 billion (≈USD 199 million) in revenue, with overseas NGP sales more than doubling year-over-year.
Nov.06
China Qingdao Jiaodong Airport Customs Seizes 430 Disposable E-Cigarettes and 8600ml of E-Liquid
China Qingdao Jiaodong Airport Customs Seizes 430 Disposable E-Cigarettes and 8600ml of E-Liquid
Qingdao Jiaodong Airport customs seized 430 disposable e-cigarettes with 8600ml e-liquid, exceeding personal duty-free limits. Items detained for legal processing.
Oct.14 by 2FIRSTS.ai
Product | Dual-flavor, 30,000-puff SKE 2-in-1 launches across multiple UK distributor platforms.
Product | Dual-flavor, 30,000-puff SKE 2-in-1 launches across multiple UK distributor platforms.
E-cigarette brand SKE has listed its “30K Pro Max” bundle across multiple UK e-commerce platforms. The 2-in-1 device features dual flavors with a twist-to-switch design, draw activation, and mesh heating, with a claimed total of up to 30,000 puffs. Across several channels, single-unit pricing ranges from about £8.99 to £10.99.
Oct.24 by 2FIRSTS.ai
BAT acquires state-owned shares of UZBAT in Uzbekistan for $22.3 million
BAT acquires state-owned shares of UZBAT in Uzbekistan for $22.3 million
British American Tobacco (BAT) acquires state-owned shares of UZBAT, a joint venture in Uzbekistan, for $22.3 million.
Oct.15 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai